Wang Lei, Su Zhong, Xie Chunying, Li Ruijun, Pan Wei, Xu Lu, Chen Fei, Cheng Gang
Department of Medical Oncology, The Afflicted Bozhou Hospital of Anhui Medical University, Bozhou, China.
Department of Oncology, Shandong Zouping People's Hospital, Zouping, China.
Front Oncol. 2023 May 29;13:1165437. doi: 10.3389/fonc.2023.1165437. eCollection 2023.
Fondaparinux is a synthetic anticoagulant for the prevention of venous thromboembolism (VTE), and its administration in Chinese cancer patients is rarely reported. This study aimed to assess the efficacy and safety of fondaparinux in preventing VTE in Chinese cancer patients.
A total of 224 cancer patients who received fondaparinux treatment were reviewed in this single-arm, multicenter, retrospective study. Meanwhile, VTE, bleeding, death, and adverse events of those patients in the hospital and at 1 month after treatment (M1) were retrieved, respectively.
The in-hospital VTE rate was 0.45% and there was no (0.00%) VTE occurrence at M1. The in-hospital bleeding rate was 2.68%, among which the major bleeding rate was 2.23% and the minor bleeding rate was 0.45%. Moreover, the bleeding rate at M1 was 0.90%, among which both the major and minor bleeding rates were 0.45%. The in-hospital death rate was 0.45% and the death rate at M1 was 0.90%. Furthermore, the total rate of adverse events was 14.73%, including nausea and vomiting (3.13%), gastrointestinal reactions (2.23%), and reduced white blood cells (1.34%).
Fondaparinux could effectively prevent VTE with low bleeding risk and acceptable tolerance in cancer patients.
磺达肝癸钠是一种用于预防静脉血栓栓塞症（VTE）的合成抗凝剂，在中国癌症患者中的应用报道较少。本研究旨在评估磺达肝癸钠预防中国癌症患者VTE的有效性和安全性。
在这项单臂、多中心、回顾性研究中，对总共224例接受磺达肝癸钠治疗的癌症患者进行了评估。同时，分别收集这些患者在住院期间以及治疗后1个月（M1）时的VTE、出血、死亡及不良事件情况。
住院期间VTE发生率为0.45%，M1时无（0.00%）VTE发生。住院期间出血率为2.68%，其中大出血率为2.23%，小出血率为0.45%。此外，M1时出血率为0.90%，其中大出血率和小出血率均为0.45%。住院期间死亡率为0.45%，M1时死亡率为0.90%。此外，不良事件总发生率为14.73%，包括恶心呕吐（3.13%）、胃肠道反应（2.23%）和白细胞减少（1.34%）。
磺达肝癸钠可有效预防癌症患者发生VTE，出血风险低且耐受性可接受。
